Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : Commercial agreement with Doctors on Demand in Australia

07/05/2021 | 02:44am EDT

View printer-friendly version

  • Doctors on Demand will integrate ResAppDx and SleepCheck into its online consultation offerings
  • Agreement includes exchange of key data to support future reimbursement submissions
  • Doctors on Demand are one of Australia's largest private telehealth businesses
  • Doctors on Demand provide both B2C and B2B offerings, with customers including Flight Centre, Allianz Partners and one of the world's largest mining companies

Brisbane, Australia, 5 July 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, has signed a commercial agreement with Australian-based telehealth company Doctors on Demand. Doctors on Demand will launch ResApp's smartphone-based acute respiratory diagnostic test ResAppDx in their video telehealth services in the third quarter of this calendar year.

Launched in 2015, Doctors on Demand offers both direct-to-consumer (B2C) and business-to-business (B2B) offerings for patients with a wide array of telehealth services including GP's, psychiatrists and dietitians along with direct connection to 3,623 pharmacies for prescription fulfilment. Doctors on Demand's B2B customers include Flight Centre, Allianz Partners and one of the world's largest mining companies.

ResAppDx uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's built-in microphone. It is CE Marked in Europe and TGA approved for ARTG listing in Australia.

The deal also includes promotion of ResApp's SleepCheck within Doctors on Demand's virtual sleep clinic. SleepCheck is ResApp's clinically accurate, hassle-free sleep apnoea screening test that provides a risk of sleep apnoea based upon breathing and snoring sounds during sleep.

Kirsty Garrett, CEO of Doctors on Demand said: 'Doctors on Demand has built its growth through innovation and delivering the highest standards of medical care for the benefit of our B2C and B2B customers. We believe ResApp Health is offering world leading diagnostic support for the telehealth industry, which enables more patients to be effectively managed through this important setting. We're very pleased to have reached this innovative agreement. Our team are very excited to implement this impressive technology to support the highest standards of care in clinical practice for our respiratory patients wherever they are in Australia, whether that's at a remote mine site in the Pilbara or student accommodation in Sydney. We believe our collaboration with ResAppDx will support both organisations to continue to innovate in the delivery of remote care.'

CEO and Managing Director of ResApp, Dr Tony Keating said: 'We are excited to have partnered with Doctors on Demand, one of Australia's leading telehealth providers. This partnership will allow us to grow our volume within our home market and importantly will provide us with real world data to support our evidence base for future reimbursement submissions for ResAppDx. We look forward to working closely with Doctors on Demand to improve the remote management of respiratory disease in Australia.'

Agreement details:
Doctors on Demand and ResApp Health have entered into an initial one-year partnership agreement (with the option of a mutually agreed additional year) for ResAppDx and SleepCheck to be implemented within the Doctors on Demands platforms for B2C and B2B customers. The agreement will see ResApp Health and Doctors on Demand collaborate to improve the patient experience and models of care for the remote management of respiratory disease (including sleep apnoea) and includes an exchange of deidentified patient data. The Agreement licenses the ResAppDx SDK to Doctors on Demand for their non-exclusive use in Australia. Doctors on Demand will also promote the SleepCheck app to its 125,000 patients as part of its virtual care offering. Either party may terminate the agreement by giving 90 days' notice. At this point in time, ResApp Health does not expect this agreement to have a material impact on the company's operating results.

###

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Disclaimer

ResApp Health Limited published this content on 05 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 July 2021 06:43:01 UTC.


ę Publicnow 2021
All news about RESAPP HEALTH LIMITED
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
MT
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
PU
09/19Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in ..
CI
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
MT
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
PU
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
CI
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
MT
08/31RESAPP HEALTH : ResAppDx receives regulatory approval in Indonesia
PU
08/31ResApp Health Limited Receives Regulatory Approval in Indonesia
CI
08/26ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,93 M -4,93 M
Net cash 2021 6,40 M 4,65 M 4,65 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 64,4 M 46,9 M 46,9 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 84,4%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED-11.76%47
SNAP INC.59.94%132 215
ANGI INC.-1.17%7 260
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-47.59%4 958
CONTEXTLOGIC INC.-66.12%3 781